Correlation between therapy, adverse events and hematological/biochemical parameters

ATRA 45 mg/m2/d Idarubicin 12 mg/m2/d Day of induction therapy Adverse events WBC N PB Hb PLT FD D-D PT PTT LDH CRP
Started 1 16.68 4.5 59 9 66 88 12429 1.27 0.97 2216 1.74
Interrupted 2 Differentiation syndrome 23.47 5.9 70 11.4 63 136 3633 1.07 0.77 1587 2.21
1st Infusion 3 Bradycardia 49.90 5.99 79 10.2 25 117 34762 1.36 0.87 18440 8.38
4 35.67 7.49 63 9 26 231 38773 1.24 0.79 16700 9
2nd Infusion 5 19.86 6.16 52 9.5 39 189 38167 1.19 0.76 9592 12.27
Resumed at 50% 6 13.23 5.03 34 10.4 54 116 27330 1.15 0.73 5249 5.11
3rd Infusion 7 5.98 2.09 28 10.6 48 67 17797 1.21 0.77 3456 1.7
8 1.39 NE NE 9.4 29 105 12442 1.19 0.74 2138 0.97
4th Infusion 9 0.7 NE NE 9.2 61 97 12203 1.2 0.72 1700 0.6
10 0.4 NE NE 8.5 45 126 9643 1.12 0.74 1330 0.42
11 0.3 NE NE 9.5 49 117 9021 1.14 0.77 1085 0.33
Resumed at 100% 12 0.15 NE NE 9.6 69 124 6575 1.19 0.75 978 0.24
Interrupted 13 Ischemic segmentary ileitis 0.12 NE NE 10.2 40 128 6273 1.14 0.72 893 0.53
14 0.05 NE NE 9.8 49 248 9265 1.36 0.87 800 4.4
15 Paroxysmal supraventricular tachycardia 0.07 NE NE 12.1 50 382 8559 1.38 0.92 710 29.98
16 0.05 NE NE 11.1 24 490 5191 1.45 0.93 641 43.48
17 Pulmonary emboly 0.06 NE NE 12.3 33 786 4902 1.32 1.04 532 40.71
18 0.09 NE NE 11 41 799 3345 1.12 0.91 498 35.45
19 0.1 NE NE 11 38 430 6565 1.05 0.75 494 13.78
20 0.21 NE NE 11 18 279 4496 1.23 0.85 623 6.65
Resumed at 100% 30 Ischemic segmentary ileitis 3.42 3.1 0 8.7 261 580 1535 1.16 0.92 550 5.1
Interrupted 31 Differentiation syndrome 3.78 3.36 0 9.7 291 449 1230 1.12 0.96 532 4.96

WBC: white blood cells, 109/L; N: neutrophils, 109/L; PB: peripheral blasts, %; Hb: hemoglobin, g/dL; PLT: platelets, 109/L; FD: fibrinogen, mg/dL; D-D: D-dimer, ng/mL; PT: prothrombin time; PTT: partial thromboplastin time; LDH: lactic dehydrogenase, U/L; CRP: C-reactive protein, g/dL; NE: not evaluable